SUMMARY Background
Gut dysbiosis may contribute to pain and bloating in patients with functional gastrointestinal disease.
Aims
To determine if treatment with rifaximin would improve the symptoms of functional dyspepsia in Chinese patients in a double-blinded, randomised, placebo-controlled trial.
Methods
Consecutive subjects with a diagnosis of functional dyspepsia as per the Rome III criteria were randomised to receive rifaximin 400 mg or placebo, all taken three times daily for 2 weeks. The investigators and study subjects were blinded to the treatment allocation. Subjects were followed up for 8 weeks. The primary end point was adequate relief of global dyspeptic symptoms (GDS). Secondary endpoints were relief of individual dyspeptic symptoms.
Results
Eighty-six subjects were recruited. At week 8, there were significantly more subjects in the rifaximin than in the placebo group who experienced adequate relief of GDS (78% vs. 52%, P = 0.02). A trend favouring rifaximin group was also noted in the preceding 4 weeks. Rifaximin was also superior to placebo in providing adequate relief of belching and post-prandial fullness/bloating (PPF) in subjects at week 4. Subgroup analysis revealed that female subjects had more significant response to rifaximin treatment (adequate relief of GDS at week 4: 76% vs. 42%, P = 0.006; week 8: 79% vs. 47%, P = 0.008), as well as improvements in their belching and PPF at week 4. The incidences of adverse effects were similar in both groups.
Conclusions
Treatment with 2 weeks of rifaximin led to adequate relief of global dyspeptic symptoms, belching and post-prandial fullness/bloating in subjects with functional dyspepsia. The difference was more marked in females. (clinicaltrials.org NCT01643083).
INTRODUCTION
Functional Dyspepsia is common, affecting 12-15% of the general population. In Asia, functional dyspepsia is often two to three times more common than irritable bowel syndrome (IBS). [1] [2] [3] The management of functional dyspepsia in Asia is nuanced by cultural/linguistic factors which impact on the phenotype of functional gastrointestinal disorders. For example, in the English nomenclature, bloating and distension are two distinct symptom complexes yet in Chinese, only one word, 'zhang' exists to describe both symptoms. 4 Furthermore, subjects with IBS in Asia tend to have more upper abdominal symptoms and may be misclassified as functional dyspepsia if a careful stool habit history is not undertaken. 5, 6 This may account in part for the low observed rates of IBS in Asia.
The aetiology of functional dyspepsia is generally considered to be multifactorial and a variety of treatment options are used including acid suppression with proton pump inhibitors, eradication of Helicobacter pylori and modulation of visceral hypersensitivity. 1, 7 Unfortunately, none of these treatments perform well in high quality studies. Recently, there has been a shift of focus to the gut microenvironment in the pathogenesis of functional gastrointestinal disorders. To illustrate the potential role of gut microbiota on the pathogenesis of IBS, Pimentel and colleagues demonstrated significant improvement in abdominal pain and bloating in patients with nonconstipated IBS who were treated with rifaximin, a nonabsorbable systemic antibiotic. 8 Furthermore, Sharara and colleagues demonstrated that treatment with rifaximin was efficacious in treating abdominal bloating and flatulence in subjects with chronic functional bloating/flatulence syndromes. 9 The rationale for the use of rifaximin in functional dyspepsia is twofold. First, rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia. A recent small study by Zhong and colleagues demonstrated that duodenal bacterial load is directly correlated with symptom severity in functional dyspepsia, suggesting a possible role of antibiotics in functional dyspepsia. [7] [8] [9] [10] [11] Furthermore, multiple researchers have found an increase in eosinophils in the duodenum of subgroups of functional dyspepsia subjects with concomitant low level of duodenal inflammation and increased permeability. In one small study, it was found to be associated with an improved response to H. pylori/antibiotic therapy, further supporting the role of antibiotics in improving the duodenal microbiome in subjects with functional dyspepsia. [12] [13] [14] Finally, rifaximin appears to alter the gut microenvironment with mechanisms of action that extend beyond its activity as an antibiotic, including prevention of gut inflammation and reduction in visceral hyperalgesia, both important in the pathogenesis of functional dyspepsia.
11, 15
Herein, we postulate that an abnormality of the gut microenvironment contributes to symptoms of functional dyspepsia which can be rectified by treatment with rifaximin. This feasibility study aims to investigate the role of rifaximin in the treatment of patients with functional dyspepsia, as defined by the Rome III criteria, in the absence of IBS. 16 
METHODS

Study subjects
This was a double-blind, placebo-controlled, randomised trial initiated by the investigators. All patients were recruited from the Gastroenterology out-patient clinics of the Queen Mary and the Tung Wah Hospitals, which are respectively tertiary and secondary referral centres in Hong Kong. Consecutive adult patients, aged 18-80 years, who fulfilled the Rome III criteria for functional dyspepsia and had a normal gastroscopy within the last 2 years were eligible. Gastroscopy was routinely performed for patients referred with uninvestigated dyspepsia prior to the institution of any prescribed therapy due to the high prevalence of H. pylori infection as well as gastroduodenal pathology in Hong Kong. Patients should be negative for H. pylori by either the rapid urease test or histopathological examination. Patients were further classified into epigastric pain syndrome and post-prandial distress syndrome as defined by Rome III. 16 There was a 2-week screening period prior to randomisation where all eligible subjects had a baseline lactulose hydrogen breath test to exclude small intestinal bacterial overgrowth. All potential eligible patients were asked about their dyspeptic symptoms at baseline and during follow-up. The global dyspeptic symptom and individual dyspeptic symptoms of epigastric pain and/or discomfort, abdominal pain and/or discomfort, post-prandial fullness/bloating, belching, flatulence, nausea and/or vomiting and fatigue were rated on a 4-point Likert scale from 0 to 3 (0 = no symptom, 1 = mild symptoms which were easily ignored, 2 = moderate symptoms which interfered with activities of daily living and 3 = severe symptoms which interfered with activities of daily living causing absenteeism etc.). Early satiation was not assessed in our study population as the Chinese translation for early satiety could not be consistently understood by Cantonese speaking patients. Subjects were recruited if they had persistent active dyspeptic symptoms within the last 1 month and during the 2-week screening period. Active dyspeptic symptoms were defined as global dyspeptic score of ≥2, or in subjects with a baseline global dyspeptic score of 1 but associated with an individual symptom score of ≥2 in either the post-prandial fullness and/or epigastric pain/discomfort subscore.
Patients with typical biliary colic or gastroesophageal reflux disease were not enrolled. We also excluded subjects with symptoms fulfilling the Rome III criteria for IBS, even if the subject had no known diagnosis of IBS. IBS was defined as a change in stool form or frequency associated with epigastric/abdominal pain or discomfort which was relieved by defecation. Furthermore, subjects were excluded if they had a change in stool frequency and stool form which was associated with the onset of their epigastric/abdominal discomfort. 17 Subjects were also excluded if they had a history of diabetes, human immunodeficiency virus infection, renal failure, previous gastric or intestinal surgery, were pregnant or breastfeeding. Subjects who took traditional Chinese medicine, proton pump inhibitors, nonsteroidal anti-inflammatory drugs, aspirin or antibiotics within the last 8 weeks were also excluded. All subjects provided informed written consent for participation into this study. The study protocol was approved by the University of Hong Kong and Hospital Authority (Hong Kong West Cluster) Institutional Review Board. The study was registered with clinicaltrials.org (NCT01643083).
Treatment allocation
Eligible patients with persistent active dyspeptic symptoms were randomised in a 1:1 ratio to receive rifaximin 1200 mg given at 400 mg three times per day (Xifaxan, Alfa Wassermann, Bologna, Italy) or identical looking placebo tablets also given three times per day for 14 days. This dosing of rifaximin was used as the 400 mg tablet of rifaximin was the only formulation available in Hong Kong. Randomisation was performed by computer generated random codes in blocks of 10. To ensure adequate blinding, all rifaximin and placebo tablets were pre-packaged in identical looking blister pack and labelled according to randomisation sequences for individual patient. At week 2, any unconsumed medications were returned and counted to check for drug compliance. The investigators, research assistants and subjects were all blinded to the study medication allocations.
Symptom assessment
Enrolled subjects completed a questionnaire, which examined subject's demographics and use of dyspeptic medications. The severity of dyspeptic symptoms, stool frequency and the stool form (assessed by Bristol Stool Chart) were also assessed at baseline. Subjects were reviewed again at week 2 (end of treatment), 4 and 8 after randomisation for repeated symptom assessments. 17 Any potential adverse events related to study medication were recorded during follow-up.
Breath tests
A baseline lactulose hydrogen breath test were utilised to exclude small bowel bacterial overgrowth, which was defined as an early peak on the hydrogen breath test over 20 parts per million (ppm) above basal breath hydrogen and followed by a second peak. This definition was utilised as previous Asian studies indicated that the median and mean oro-caecal transit times fall between 65 and 85 min. 18, 19 Breath samples were collected for a total of three hours at 15-min intervals after an overnight fast. The dose of lactulose (Abbott Healthcare Products, Weesp, The Netherlands) was 10 g. Breath samples were analysed using a hand-held breath hydrogen monitor (Gastrolyzer, Bedfont Scientific, Kent, UK). 20 
Outcome measures
The primary outcome of this study was adequate relief of global dyspeptic symptoms at week 4 and 8. Adequate relief of global dyspeptic symptoms was defined as a global dyspeptic symptom score of 0 or 1. In the cohort of subjects who had a baseline global dyspeptic symptoms score of 1, the individual subscore(s) in epigastric pain/ discomfort and/or post-prandial fullness must be ≤1 to be counted as adequate relief of global dyspeptic symptoms in the final analysis. Secondary outcomes included adequate relief of individual dyspeptic symptom subscore of ≤1 at week 4 and 8.
Sample size estimation
This was a feasibility study assessing the efficacy of rifaximin in patients with functional dyspepsia. While the usual placebo response rate in functional gastrointestinal disease trials is around 30%, we assume that 60% of patients in the rifaximin group would have adequate relief of global dyspeptic symptoms. 6, 7 With a statistical power of 80% and one-sided significance levels at 5%, 40 patients were required in each study arm. Assuming 10% of patients would drop out or lost to follow-up, this study would recruit 88 subjects in total.
Statistical analysis
Analysis was based on both the intention-to-treat (ITT) and per-protocol population. The ITT analysis included all patients who had a complete baseline assessment and received at least one dose of the study drug in the treatment phase but excluded patients who did not receive any study medications for various reasons. Missing binary data were carried forward from the last eligible follow-up period. Missing continuous data were imputed using the overall mean of the nonmissing data. Binary data were analysed by logistic regression and continuous data were compared by student t-test. A two-sided Pvalue of less than 0.05 is considered to be statistically significant.
RESULTS
Study population
Ninety-five consecutive subjects who fulfilled the Rome III criteria for functional dyspepsia were enrolled to this study between June 2012 and April 2014. Nine subjects were excluded for ITT analysis for reasons as shown in Figure 1 including patients with post-randomisation exclusion. In total, 86 patients were included in the ITT analysis which included 40 in the rifaximin group and 46 in placebo group. The demographics and baseline characteristics of patients were similar between the two groups (Table 1 ). There were more female patients (76%) in this study and the mean age of these patients was 53.4 (s.d. = 12.5) years. No study subject had evidence of small intestinal bacterial overgrowth on lactulose hydrogen breath test at baseline. 34 (85%) and 38 (83%) subjects in the rifaximin and placebo groups took more than 75% of the study medications (P = 0.76), respectively, and were included in the per-protocol analysis.
Outcomes
The percentage of patients with adequate relief of global dyspeptic symptoms in both treatment groups was shown in ( (Table S2) . Further analysis was performed to include only patients with baseline Global Dyspeptic Symptom of ≥2 with similar trends observed (Table S3) . We further analysed the potential gender difference in treatment responses to rifaximin (Figure 2) . At week 4, In terms of belching and postprandial fullness/bloating, female subjects who were randomised to rifaximin also experienced significant improvement when compared to placebo at week 4. However, this improvement was not significant at week 8 although a trend favouring rifaximin was still evident.
Similar improvements of the global dyspeptic symptom or individual dyspeptic symptoms were not seen in male patients.
Adverse events
Adverse events of the two groups are listed in Table 3 . Overall, there was no significant difference in the number of cumulative adverse events between the rifaximin and placebo groups (20% vs. 30%, P = 0.27). There was one serious adverse event in a patient in the placebo group who developed acute hepatitis 1 week after commencing the study medications, which may have been related to illicit use of traditional Chinese medicine. 
DISCUSSION
This is the first double-blinded, placebo-controlled randomised study to examine the efficacy of rifaximin in subjects with Rome III criteria defined functional dyspepsia. We found that rifaximin is superior to placebo for the relief of global dyspeptic symptoms, post-prandial fullness/bloating and belching. In particular, subgroup analyses revealed that female subjects experienced more remarkable and sustained improvement in their global dyspeptic symptoms, as well as improvement in their post-prandial bloating and belching at week 4. Treatment with rifaximin did not lead to an excess of adverse events when compared with placebo.
There is currently limited data to explain the therapeutic effect of rifaximin in functional dyspepsia or even in IBS. 11 Emerging data which may account for the effectiveness of rifaximin in functional dyspepsia include rifaximin's role on the gut microbiota as an antibiotic, its proclivity for the duodenum, its action on the upper gastrointestinal microenvironment and modulation of visceral hypersensitivity. The current understanding of functional dyspepsia presumes that pathophysiology originating from the gastroduodenal region is the key, while IBS is presumed to have an intestinal basis. Rifaximin's effectiveness in IBS is presumed to arise from rifaximin's antibiotic effect on the small intestinal and colonic microbiota. 8, 9, 11 This may also be the mechanism by which rifaximin exerts its effect in functional dyspepsia. The importance of intimate gut-brain and brain-gut interactions in functional gastrointestinal disease is well recognised. However, understanding the intimate connections between upper and lower gastrointestinal function is still in its infancy. The gastro-colic reflex is well understood, but how modulation of lower gastrointestinal function impacts on the upper gastrointestinal symptoms is not well understood. The colo-gastric reflex, demonstrated in animal studies, shows that colonic distension inhibits gastric adaptive relaxation and this may be the basis of a change in the colonic microbiota's effect on dyspeptic symptoms. 21 In humans, limited indirect evidence exists for the influence of lower gastrointestinal function on upper gastrointestinal symptoms. In the study by Ong and colleagues, IBS patients randomised to high versus low FODMAP diets found that a high FOD-MAP diet induced upper gastrointestinal symptoms including nausea and heartburn. 22 Furthermore, a study in paediatric subjects with functional dyspepsia and constipation demonstrated that gastric emptying and dyspeptic symptoms improved with the use of laxatives and increased frequency of bowel motions. 23 However, rifaximin's effect may not be exclusively confined to the small intestine and colon. Recently, studies have identified microscopic duodenitis in a subgroup of functional dyspepsia subjects and demonstrated its association with a range of symptoms including early satiety, post-prandial fullness and abdominal pain. 12, 14, 24 Furthermore, in one study where subjects underwent H. pylori eradication, there appeared to be an increased symptomatic response in subjects with demonstrable microscopic duodenitis. This seems to suggest an effect of antibiotics in the duodenal microbiome in functional dyspepsia subjects which is distinct from the effect of H. pylori eradication.
14 Hence, rifaximin's mechanism of action in this study was postulated to be as an antibiotic in the duodenal microbiome. This postulation is further supported by a small clinical study by Zhong and colleagues which found that the bacterial load in the duodenum correlated positively with the symptoms severity and negatively with the bacterial diversity. 10 In addition, in animal studies, bile acids augment rifaximin's effect through increased solubility, suggesting that rifaximin's efficacy may be maximal in the duodenum and proximal small intestine. 11 Finally, rifaximin appears to prevent gut inflammation, reduces visceral hyperalgesia and act as a gut environment modulator. 15 In summary, rifaximin has multiple plausible mechanisms by which it may lead to improvements in dyspeptic symptoms in functional dyspepsia, future mechanistic studies are required to confirm the mechanism(s) of action.
One of the main difficulties with performing studies on subjects with functional dyspepsia is the absence of reliable biomarker. In fact, patient's symptoms correlate poorly and inconsistently with putative pathophysiological mechanisms including gastric emptying rates. As a consequence, the response to treatment in functional dyspepsia studies is largely dependent on patient selfreported symptom intensities. The overall treatment effect allows patients to integrate all aspects of their condition into a single treatment outcome and it is the way doctors and patients evaluate response to treatment in clinical practice. Our study's strength derives from its assessment of both overall treatment effect and individual clinically important symptoms. 25 In the absence of a regulatory guideline on the magnitude of active drug response rate over placebo to be considered clinically relevant, an expert group suggested 10-15% over placebo would constitute a clinically meaningful outcome. In our study, both ITT and per-protocol analysis has demonstrated a 20-30% improvement over placebo on the global dyspeptic symptom, symptoms of post-prandial bloating and belching in the female subgroup. These findings indicate that our study is well placed to demonstrate the effect of rifaximin on symptom improvement in functional dyspepsia. 25 Another important aspect of our study is that we actively excluded subjects who had symptoms suggestive of or had a diagnosis of IBS, so that we were not studying subjects with functional dyspepsia/IBS overlap. In the Asia Pacific region, numerous studies have indicated that the reason for the higher prevalence of functional dyspepsia as compared to IBS is partly related to misdiagnosis of IBS as functional dyspepsia. 5, 6 In this region, patients are less likely to volunteer their bowel habit abnormalities (this may be cultural) or even perceive that their bowel habit may be normal. The fact that no study subject experienced relief of their dyspeptic symptoms with defecation and at baseline 95.3% of our study subjects had a stool frequency of between 3 and 21 bowel actions per week and 88.4% had a Bristol Stool Chart score of between 3 and 5 again reaffirms that our study directly examined the effect of rifaximin in functional dyspepsia subjects only in the absence of IBS. 4, 6, 17 This study had a number of limitations. First, it is a small feasibility study involving only two centres and the study design did not enable an assessment of the mechanisms underlying rifaximin's effectiveness, particularly on individual dyspeptic symptom. Second, assessment of early satiety was not performed in this study due to issues with the Chinese translation. Third, while there was significant improvement of global dyspeptic symptoms at week 8, the durability of the treatment response to rifaximin is unknown. A longer follow-up duration, like up to 12-week, may be necessary to determine the durability or the optimal treatment duration in future studies. There also appeared to have a difference in the time frame of treatment responses between global dyspeptic symptom and individual symptom such as post-prandial fullness/bloating and belching. However, in subgroup analysis of female patients, we found that there was a significant improvement of global dyspeptic symptom as early as week 4. Hence, the lack of significant difference at week 4 in the whole group analysis may be due to the small sample size of this study and the differential gender response to rifaximin. Fourth, there was a higher than expected placebo response rate in our study, although the placebo response rate in functional dyspepsia studies is usually high. We speculate that the three times daily dosing of both rifaximin and placebo tablets may have contributed to this observation. However, the only available dosing of rifaximin in Hong Kong is the 400 mg tablet instead of the 550 mg tablet used in North America. Finally, as our study group comprised of predominantly females and all were functional dyspepsia subjects without IBS, this limits the generalisability of our results as studies in this region indicate that functional dyspepsia and IBS frequently overlap. 4 The mean age of our patients was also older than usually reported in western patients, which may reflect the longer life expectancy in East Asia. In summary, this double blind, randomised, placebocontrolled trial is the first study to demonstrate that rifaximin is efficacious in the treatment of functional dyspepsia, particularly for relief of global dyspeptic symptoms and individual dyspeptic symptoms of postprandial fullness/bloating and belching. Larger studies to confirm this result and mechanistic studies to determine the drivers of a response to rifaximin are warranted.
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Additional Supporting Information may be found in the online version of this article: Table S1 . Per-protocol analysis, percentage of patients with adequate relief of global dyspeptic and individual dyspeptic symptoms. Table S2 . Percentage of patients with adequate relief of other individual dyspeptic symptoms based on ITT analysis. Table S3 . Subgroup analysis, subjects with global dyspepsia score of ≥2 at baseline.
